ID

37386

Description

Sitagliptin and Glucagon Counterregulation; ODM derived from: https://clinicaltrials.gov/show/NCT02256189

Link

https://clinicaltrials.gov/show/NCT02256189

Keywords

Versions (1)
  1. 7/21/19 7/21/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 21, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Type 2 Diabetes NCT02256189

English

Eligibility Type 2 Diabetes NCT02256189

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. written consent has been given.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
2. patients with metformin treated t2dm (metformin dose >1.0 g/day and stable during the preceding 3 months)
Description

Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable U/day

Data type

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0025598
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [2,4]
C0456683
3. age >65 years.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
4. hba1c 6.5-8.5% (48-67 mmol/mol; inclusive) at visit 1.
Description

Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1]
C0474680
5. ability to complete the study
Description

Completion of clinical trial Able

Data type

boolean

Alias
UMLS CUI [1,1]
C2732579
UMLS CUI [1,2]
C0085732
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
Description

Secondary diabetes mellitus | Cushing Syndrome | Acromegaly

Data type

boolean

Alias
UMLS CUI [1]
C0271640
UMLS CUI [2]
C0010481
UMLS CUI [3]
C0001206
2. type 2 diabetes, positive gad antibodies
Description

Diabetes Mellitus, Non-Insulin-Dependent | Anti-GAD antibody positive

Data type

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2]
C1167896
3. egfr <60 ml/min
Description

Estimated Glomerular Filtration Rate

Data type

boolean

Alias
UMLS CUI [1]
C3811844
4. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
Description

Communicable Diseases Affecting Blood Glucose Control

Data type

boolean

Alias
UMLS CUI [1,1]
C0009450
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0005802
UMLS CUI [1,4]
C0243148
5. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
Description

Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe

Data type

boolean

Alias
UMLS CUI [1,1]
C0745153
UMLS CUI [1,2]
C2945760
UMLS CUI [2,1]
C0745153
UMLS CUI [2,2]
C0205082
6. liver disease such as cirrhosis or chronic active hepatitis
Description

Liver disease | Liver Cirrhosis | Hepatitis, Chronic

Data type

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C0023890
UMLS CUI [3]
C0019189
7. history of coronary heart disease or heart failure class iii or iv
Description

Coronary heart disease | Heart failure New York Heart Association Classification

Data type

boolean

Alias
UMLS CUI [1]
C0010068
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
8. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
Description

Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion

Data type

boolean

Alias
UMLS CUI [1,1]
C0005794
UMLS CUI [1,2]
C0439148
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3163616
UMLS CUI [2,2]
C0439148
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0005841
9. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
Description

Growth hormone treatment | Corticosteroid therapy oral chronic | Corticosteroid therapy parenteral chronic

Data type

boolean

Alias
UMLS CUI [1]
C0744483
UMLS CUI [2,1]
C0149783
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C0205191
UMLS CUI [3,1]
C0149783
UMLS CUI [3,2]
C1518896
UMLS CUI [3,3]
C0205191
10. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
Description

Investigational New Drugs Inappropriate Clinical Trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0013230
UMLS CUI [1,2]
C1548788
UMLS CUI [1,3]
C0008976
Back to the top of the page

Similar models

Eligibility Type 2 Diabetes NCT02256189

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. written consent has been given.
boolean
C0021430 (UMLS CUI [1])
Diabetes Mellitus, Non-Insulin-Dependent | Metformin Dose Stable U/day
Item
2. patients with metformin treated t2dm (metformin dose >1.0 g/day and stable during the preceding 3 months)
boolean
C0011860 (UMLS CUI [1])
C0025598 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0456683 (UMLS CUI [2,4])
Age
Item
3. age >65 years.
boolean
C0001779 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
4. hba1c 6.5-8.5% (48-67 mmol/mol; inclusive) at visit 1.
boolean
C0474680 (UMLS CUI [1])
Completion of clinical trial Able
Item
5. ability to complete the study
boolean
C2732579 (UMLS CUI [1,1])
C0085732 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Secondary diabetes mellitus | Cushing Syndrome | Acromegaly
Item
1. a history of any secondary forms of diabetes, e.g., cushing's syndrome and acromegaly.
boolean
C0271640 (UMLS CUI [1])
C0010481 (UMLS CUI [2])
C0001206 (UMLS CUI [3])
Diabetes Mellitus, Non-Insulin-Dependent | Anti-GAD antibody positive
Item
2. type 2 diabetes, positive gad antibodies
boolean
C0011860 (UMLS CUI [1])
C1167896 (UMLS CUI [2])
Estimated Glomerular Filtration Rate
Item
3. egfr <60 ml/min
boolean
C3811844 (UMLS CUI [1])
Communicable Diseases Affecting Blood Glucose Control
Item
4. acute infections which may affect blood glucose control within 4 weeks prior to visit 1
boolean
C0009450 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005802 (UMLS CUI [1,3])
C0243148 (UMLS CUI [1,4])
Hypoglycaemic episode Recurrent | Hypoglycaemic episode Severe
Item
5. any history of recent (<2 weeks) recurrent or severe hypoglycemic episodes.
boolean
C0745153 (UMLS CUI [1,1])
C2945760 (UMLS CUI [1,2])
C0745153 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
Liver disease | Liver Cirrhosis | Hepatitis, Chronic
Item
6. liver disease such as cirrhosis or chronic active hepatitis
boolean
C0023895 (UMLS CUI [1])
C0023890 (UMLS CUI [2])
C0019189 (UMLS CUI [3])
Coronary heart disease | Heart failure New York Heart Association Classification
Item
7. history of coronary heart disease or heart failure class iii or iv
boolean
C0010068 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
Blood Donation Unit Quantity | Blood Loss Unit Quantity | Blood Transfusion
Item
8. donation of one unit (500 ml) or more of blood, significant blood loss equaling to at least one unit of blood within the past 2 weeks or a blood transfusion within the past 8 weeks.
boolean
C0005794 (UMLS CUI [1,1])
C0439148 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3163616 (UMLS CUI [2,1])
C0439148 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0005841 (UMLS CUI [3])
Growth hormone treatment | Corticosteroid therapy oral chronic | Corticosteroid therapy parenteral chronic
Item
9. treatment with growth hormone of chronic oral or parenteral corticosteroid treatment (> 7 consecutive days of treatment) within 8 weeks prior to visit 1.
boolean
C0744483 (UMLS CUI [1])
C0149783 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C0205191 (UMLS CUI [2,3])
C0149783 (UMLS CUI [3,1])
C1518896 (UMLS CUI [3,2])
C0205191 (UMLS CUI [3,3])
Investigational New Drugs Inappropriate Clinical Trial
Item
10. use of other investigational drugs at visit 1 or within 30 days of visit 1, unsuitable for the study
boolean
C0013230 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial